The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ATM or CHEK2 alterations: Potential biomarkers of improved outcomes with irinotecan-containing chemotherapy in advanced pancreatic ductal adenocarcinoma.
 
Maahum Mehdi
No Relationships to Disclose
 
Bicky Thapa
No Relationships to Disclose
 
Aniko Szabo
No Relationships to Disclose
 
Gulrayz Ahmed
No Relationships to Disclose
 
Aditya V. Shreenivas
Consulting or Advisory Role - Taiho Pharmaceutical (Inst)
Research Funding - Natera (Inst)
 
James P. Thomas
No Relationships to Disclose
 
Deepika Sriram
No Relationships to Disclose
 
Douglas B. Evans
No Relationships to Disclose
 
Susan Tsai
No Relationships to Disclose
 
Kathleen K. Christians
No Relationships to Disclose
 
Beth Erickson
Research Funding - Elekta (Inst)
 
William A. Hall
Research Funding - Elekta (Inst)
Travel, Accommodations, Expenses - Elekta (Inst)
 
Thomas McFall
No Relationships to Disclose
 
Steve Patrick
No Relationships to Disclose
 
Ben George
Consulting or Advisory Role - Bayer; Boston Scientific; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Ipsen; Roche/Genentech; Taiho Pharmaceutical; TERUMO
Research Funding - Boehringer Ingelheim (Inst); GlycoNex (Inst); Helix BioPharma (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Roche (Inst); Roche/Genentech (Inst); Sirnaomics (Inst); Taiho Pharmaceutical (Inst); Tolero Pharmaceuticals (Inst); Toray Industries (Inst); Trishula Therapeutics (Inst)
 
Razelle Kurzrock
Leadership - CureMatch; CureMetrix
Stock and Other Ownership Interests - CureMatch; CureMetrix; IDbyDNA
Honoraria - AACR; Bicara Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; Foundation Medicine; LEK; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Roche; Turning Point Therapeutics; Wiley
Consulting or Advisory Role - Actuate Therapeutics; AstraZeneca; Bicara Therapeutics; Biological Dynamics; Daiichi Sankyo; Eisai; EOM Pharmaceuticals; Gaido; Iylon; Loxo; Merck; NeoMed; Pfizer; Prosperdtx; Roche; Soluventis; TD2/Volastra; Turning Point Therapeutics; XBiotech
Speakers' Bureau - NeoGenomics Laboratories; Roche
Research Funding - Biological Dynamics (Inst); Boehringer Ingelheim (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Genentech (Inst); Grifols (Inst); Guardant Health (Inst); Incyte (Inst); Konica Minolta (Inst); MedImmune (Inst); Merck Serono (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - NCI SWOG; TargetCancer Foundation
 
Mandana Kamgar
Research Funding - BostonGene; Guardant Health; Rafael Pharmaceuticals (Inst)